Jim Simons Relay Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 763,200 shares of RLAY stock, worth $4.98 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

763,200

Previous 323,700 135.77%

Holding current value

$4.98 Million

Previous $3.56 Million 77.75%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$7.5 - $12.07 $3.3 Million - $5.3 Million	439,500 Added 135.77%	763,200 $6.34 Million
Q4 2023 Feb 13, 2024	BUY	$6.01 - $11.48 $1.08 Million - $2.05 Million	179,000 Added 123.7%	323,700 $3.56 Million
Q3 2023 Nov 14, 2023	BUY	$8.24 - $12.97 $1.19 Million - $1.88 Million	144,700 New	144,700 $1.22 Million
Q1 2023 May 12, 2023	BUY	$15.0 - $22.76 $870,810 - $1.32 Million	58,054 Added 95.48%	118,854 $1.96 Million
Q4 2022 Feb 13, 2023	BUY	$14.16 - $24.02 $860,928 - $1.46 Million	60,800 New	60,800 $908,000

Q2 2022 Aug 12, 2022	SELL	$13.31 - $34.88 $25,289 - $66,272	-1,900 Reduced 6.83%	25,900 $434,000
Q1 2022 May 13, 2022	BUY	$20.26 - $32.36 $421,408 - $673,088	20,800 Added 297.14%	27,800 $832,000
Q4 2021 Feb 11, 2022	SELL	$26.0 - $37.03 $3.79 Million - $5.39 Million	-145,588 Reduced 95.41%	7,000 $215,000
Q3 2021 Nov 12, 2021	BUY	$29.75 - $37.99 $4.54 Million - $5.8 Million	152,588 New	152,588 $4.81 Million

Others Institutions Holding RLAY

# of Institutions

188

Shares Held

127M

Call Options Held

4.2K

Put Options Held

1.7K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $784M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account